---
title: 'Letermovir for Cytomegalovirus infection in pediatric patients undergoing
  allogenic hematopoietic stem cell transplantation: a real-life study by the Infectious
  Diseases Working Group of Italian Association of Pediatric Hematology-Oncology (AIEOP)'
date: '2024-01-25'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38272999/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1jUKNaekwK5-jhnLOsYRQeEvu-lGfd382Ao3uOl7PziqjjxYZK&fc=20220919201732&ff=20240126170435&v=2.18.0
source: (stem cell transplantation) AND (Cytomegalovirus pneumonia)
description: Letermovir prophylaxis revolutionized the approach to Cytomegalovirus
  infection in adult hematopoietic stem cell transplant (HCT), while data in pediatric
  setting are still lacking. We retrospectively analyzed 87 HCT children transplanted
  in 11 AIEOP centers receiving letermovir as off-label indication between January
  2020 and November 2022. Letermovir was used as primary, secondary prophylaxis or
  CMV treatment in 39, 26 and 22 cases, respectively; no discontinuation due to toxicity
  ...
disable_comments: true
---
Letermovir prophylaxis revolutionized the approach to Cytomegalovirus infection in adult hematopoietic stem cell transplant (HCT), while data in pediatric setting are still lacking. We retrospectively analyzed 87 HCT children transplanted in 11 AIEOP centers receiving letermovir as off-label indication between January 2020 and November 2022. Letermovir was used as primary, secondary prophylaxis or CMV treatment in 39, 26 and 22 cases, respectively; no discontinuation due to toxicity ...